![X4 Pharmaceuticals, Inc. logo](/logos/XFOR.webp)
X4 Pharmaceuticals, Inc.
NASDAQ:XFOR
Overview | Financials
Company Name | X4 Pharmaceuticals, Inc. |
Symbol | XFOR |
Currency | USD |
Price | 0.652 |
Market Cap | 109,777,750 |
Dividend Yield | 0% |
52-week-range | 0.531 - 1.6 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Paula Ragan Ph.D. |
Website | https://www.x4pharma.com |
An error occurred while fetching data.
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD